Multi-center, blinded, randomised, PaRallEl-group, Phase 3 study with aproCItentan in Subjects with ResIstant HypertensiON (RHT)

The primary objective of this study is to demonstrate the blood pressure (BP) lowering effect of aprocitentan when added to standard of care in true resistant hypertension (RHT) subjects.

To be eligible for inclusion participants will be:

• 18 years or older
• Documented uncontrolled BP despite 3 background hypertensive medications
• Secondary causes of hypertension excluded

For further information please phone 1800 971 022